Plain-English translation of NCT07433387 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called LP-98, which is given by injection under the skin. The study wants to learn whether this treatment works for people with HIV who have not yet started HIV medications, and whether it is safe and well-tolerated at different dose levels.
Current HIV treatments often require taking multiple pills every day for life. This medication aims to offer a simpler option—possibly with fewer doses and injections instead of daily pills—to make HIV treatment easier and help people stick with their care.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic about eight times over three months. You would receive four injections of the medication under your skin, spaced two weeks apart, at doses of either 20 mg, 40 mg, or 80 mg depending on which group you're assigned to. The study includes blood tests, heart monitoring, and follow-up visits to check how you're doing and whether the treatment is working and safe.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Sponsor
Shanxi Kangbao Biological Product Co., Ltd.
Collaborators
Institute of Pathogen Biology, Beijing, China
Enrollment target
~30 participants
Started
January 2026
Primary completion
July 2026
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yuxian He, Doctor
Tianjin Second People's Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.